Sanofi/Genzyme shift Campath to special distribution ahead of Lemtrada MS marketing
This article was originally published in Scrip
Executive Summary
In anticipation of obtaining approval of their investigational multiple sclerosis drug Lemtrada (alemtuzumab), Paris-based Sanofi and its US unit Genzyme will only be making another version of the agent, sold as Campath, available to US patients with B-cell chronic lymphocytic leukemia (B-CLL) through a special distribution program as of 4 September, a spokesman for the firms confirmed on 20 August.